DK3288581T3 - Fremgangsmåde til behandling af cancer - Google Patents
Fremgangsmåde til behandling af cancer Download PDFInfo
- Publication number
- DK3288581T3 DK3288581T3 DK16718705.3T DK16718705T DK3288581T3 DK 3288581 T3 DK3288581 T3 DK 3288581T3 DK 16718705 T DK16718705 T DK 16718705T DK 3288581 T3 DK3288581 T3 DK 3288581T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer treatment
- treatment procedure
- procedure
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1507100.4A GB201507100D0 (en) | 2015-04-27 | 2015-04-27 | Method |
GBGB1603663.4A GB201603663D0 (en) | 2016-03-02 | 2016-03-02 | Method |
GBGB1603731.9A GB201603731D0 (en) | 2016-03-03 | 2016-03-03 | Method |
PCT/EP2016/059401 WO2016174085A1 (en) | 2015-04-27 | 2016-04-27 | Method for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3288581T3 true DK3288581T3 (da) | 2021-01-11 |
Family
ID=55809140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16718705.3T DK3288581T3 (da) | 2015-04-27 | 2016-04-27 | Fremgangsmåde til behandling af cancer |
Country Status (22)
Country | Link |
---|---|
US (3) | US20180064793A1 (da) |
EP (4) | EP3288581B1 (da) |
JP (4) | JP6918703B2 (da) |
KR (2) | KR102629590B1 (da) |
CN (2) | CN107750278B (da) |
AU (2) | AU2016256220B2 (da) |
BR (1) | BR112017020893A2 (da) |
CA (1) | CA2982266A1 (da) |
CL (2) | CL2017002728A1 (da) |
DK (1) | DK3288581T3 (da) |
ES (1) | ES2836273T3 (da) |
HU (1) | HUE052106T2 (da) |
IL (2) | IL298497A (da) |
MX (1) | MX2017013777A (da) |
MY (1) | MY189338A (da) |
NZ (1) | NZ735882A (da) |
PL (1) | PL3288581T3 (da) |
PT (1) | PT3288581T (da) |
RU (2) | RU2770447C2 (da) |
SG (2) | SG10202007364RA (da) |
WO (1) | WO2016174085A1 (da) |
ZA (1) | ZA201706616B (da) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Identification of neo-antigens, preparation, and use |
US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
CA3044250A1 (en) * | 2016-11-17 | 2018-05-24 | Iovance Biotherapeutics, Inc. | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same |
EP3548897A4 (en) | 2016-12-01 | 2020-08-12 | Nantomics, LLC | PRESENTATION AND TREATMENT OF TUMOR ANTIGENICITY |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
EP3579846A1 (en) * | 2017-02-07 | 2019-12-18 | Memorial Sloan Kettering Cancer Center | Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy |
WO2018183980A2 (en) | 2017-03-31 | 2018-10-04 | Pei Jia Yang | Ranking system for immunogenic cancer-specific epitopes |
CN110913896A (zh) | 2017-07-14 | 2020-03-24 | 弗朗西斯.克里克研究所 | 肿瘤中hla等位基因的分析及其用途 |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
KR20200090855A (ko) | 2017-11-22 | 2020-07-29 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원에 대한 접합 에피토프 제시 감소 |
EP3618071A1 (en) * | 2018-08-28 | 2020-03-04 | CeCaVa GmbH & Co. KG | Methods for selecting tumor-specific neoantigens |
WO2020043805A1 (en) * | 2018-08-28 | 2020-03-05 | CeCaVa GmbH & Co. KG | Methods for ranking and/or selecting tumor-specific neoantigens |
CN109337873A (zh) * | 2018-09-30 | 2019-02-15 | 北京鼎成肽源生物技术有限公司 | 一种lrff细胞 |
CN109294997B (zh) * | 2018-09-30 | 2020-09-25 | 北京鼎成肽源生物技术有限公司 | 一种lrfft1细胞 |
CN109295097B (zh) * | 2018-09-30 | 2020-09-25 | 北京鼎成肽源生物技术有限公司 | 一种mrfft2细胞 |
CN109485721A (zh) * | 2018-11-23 | 2019-03-19 | 杜学明 | 一种获得肿瘤特异性t细胞受体的方法 |
AU2020204779A1 (en) * | 2019-01-03 | 2021-08-26 | Evaxion Biotech A/S | Vaccines targeting neoepitopes |
CN110534156B (zh) * | 2019-09-02 | 2022-06-17 | 深圳市新合生物医疗科技有限公司 | 一种提取免疫治疗新抗原的方法及*** |
CN110689930B (zh) * | 2019-10-18 | 2021-07-30 | 北京橡鑫生物科技有限公司 | 检测tmb的方法及装置 |
WO2021087839A1 (zh) * | 2019-11-07 | 2021-05-14 | 武汉华大吉诺因生物科技有限公司 | 肿瘤特异性多肽序列及其应用 |
WO2021116714A1 (en) * | 2019-12-12 | 2021-06-17 | Achilles Therapeutics Uk Limited | Method for obtaining nucleic acid for sequencing |
WO2021123832A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
US20230235008A1 (en) * | 2020-02-14 | 2023-07-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Novel t cell receptors (tcrs) that react to neoantigens |
CN111303268B (zh) * | 2020-03-10 | 2021-08-27 | 江苏兰恩生物治疗技术研究院有限公司 | 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗 |
JP2022024683A (ja) | 2020-07-28 | 2022-02-09 | 株式会社ミツトヨ | 形状測定方法 |
GB202104715D0 (en) * | 2021-04-01 | 2021-05-19 | Achilles Therapeutics Uk Ltd | Identification of clonal neoantigens and uses thereof |
GB202202880D0 (en) | 2022-03-02 | 2022-04-13 | Achilles Therapeutics Uk Ltd | Methods for peptide synthesis |
GB202205147D0 (en) | 2022-04-07 | 2022-05-25 | Achilles Therapeutics Uk Ltd | Identification of clonal neoantigens and uses thereof |
GB202205135D0 (en) | 2022-04-07 | 2022-05-25 | Francis Crick Institute Ltd | Analysis of HLA alleles transcriptional deregulation |
WO2023194491A1 (en) | 2022-04-07 | 2023-10-12 | The Francis Crick Institute Limited | Analysis of hla alleles transcriptional deregulation |
GB202210006D0 (en) | 2022-07-07 | 2022-08-24 | Achilles Therapeutics Uk Ltd | Analysis of T cell samples |
WO2024034622A1 (ja) * | 2022-08-08 | 2024-02-15 | 北海道公立大学法人 札幌医科大学 | 対象由来のネオアンチゲンを選択するための方法 |
GB202213928D0 (en) | 2022-09-23 | 2022-11-09 | Achilles Therapeutics Uk Ltd | Allele specific expression |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2209633C2 (ru) * | 1997-09-19 | 2003-08-10 | Юниверсити Оф Саузерн Калифорниа | Т-клеточная вакцина для лечения рассеянного склероза |
AU3483001A (en) * | 2000-02-04 | 2001-08-14 | Corixa Corp | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US9115402B2 (en) * | 2010-05-14 | 2015-08-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
FI3892295T3 (fi) * | 2011-05-24 | 2023-05-10 | BioNTech SE | Yksilöityjä rokotteita syöpää varten |
JP2015533473A (ja) * | 2012-07-12 | 2015-11-26 | ペルシミューン,インコーポレイテッド | 個別のがんワクチン及び適応免疫細胞療法 |
WO2014026096A1 (en) * | 2012-08-10 | 2014-02-13 | The Broad Institute, Inc. | Methods and apparatus for analyzing and quantifying dna alterations in cancer |
ES2824024T3 (es) | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
BR112015025460B1 (pt) * | 2013-04-07 | 2024-01-02 | The Broad Institute, Inc. | Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma |
WO2015014375A1 (en) * | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
CA2934073A1 (en) * | 2013-12-20 | 2015-06-25 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
TWI755157B (zh) * | 2015-03-17 | 2022-02-11 | 德商英麥提克生物技術股份有限公司 | 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合 |
GB201516047D0 (en) * | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
-
2016
- 2016-04-27 EP EP16718705.3A patent/EP3288581B1/en active Active
- 2016-04-27 HU HUE16718705A patent/HUE052106T2/hu unknown
- 2016-04-27 IL IL298497A patent/IL298497A/en unknown
- 2016-04-27 RU RU2017134504A patent/RU2770447C2/ru active
- 2016-04-27 SG SG10202007364RA patent/SG10202007364RA/en unknown
- 2016-04-27 PT PT167187053T patent/PT3288581T/pt unknown
- 2016-04-27 JP JP2017555770A patent/JP6918703B2/ja active Active
- 2016-04-27 MY MYPI2017001511A patent/MY189338A/en unknown
- 2016-04-27 DK DK16718705.3T patent/DK3288581T3/da active
- 2016-04-27 CN CN201680024518.6A patent/CN107750278B/zh active Active
- 2016-04-27 KR KR1020177034158A patent/KR102629590B1/ko active IP Right Grant
- 2016-04-27 EP EP19196027.7A patent/EP3603665A1/en active Pending
- 2016-04-27 MX MX2017013777A patent/MX2017013777A/es unknown
- 2016-04-27 EP EP22195469.6A patent/EP4137151A1/en active Pending
- 2016-04-27 NZ NZ735882A patent/NZ735882A/en unknown
- 2016-04-27 RU RU2020123735A patent/RU2020123735A/ru unknown
- 2016-04-27 US US15/569,334 patent/US20180064793A1/en active Pending
- 2016-04-27 WO PCT/EP2016/059401 patent/WO2016174085A1/en active Application Filing
- 2016-04-27 KR KR1020237027450A patent/KR20230125090A/ko active Search and Examination
- 2016-04-27 CN CN202311208886.4A patent/CN117467603A/zh active Pending
- 2016-04-27 AU AU2016256220A patent/AU2016256220B2/en active Active
- 2016-04-27 CA CA2982266A patent/CA2982266A1/en active Pending
- 2016-04-27 BR BR112017020893-8A patent/BR112017020893A2/pt active Search and Examination
- 2016-04-27 SG SG11201707920YA patent/SG11201707920YA/en unknown
- 2016-04-27 EP EP19196028.5A patent/EP3603666A1/en active Pending
- 2016-04-27 ES ES16718705T patent/ES2836273T3/es active Active
- 2016-04-27 PL PL16718705T patent/PL3288581T3/pl unknown
-
2017
- 2017-09-27 IL IL254760A patent/IL254760B2/en unknown
- 2017-10-02 ZA ZA2017/06616A patent/ZA201706616B/en unknown
- 2017-10-26 CL CL2017002728A patent/CL2017002728A1/es unknown
-
2019
- 2019-09-09 US US16/565,342 patent/US20200000903A1/en not_active Abandoned
- 2019-09-09 US US16/565,350 patent/US20200000904A1/en not_active Abandoned
-
2020
- 2020-04-07 JP JP2020069210A patent/JP2020127404A/ja active Pending
- 2020-06-24 CL CL2020001730A patent/CL2020001730A1/es unknown
-
2021
- 2021-09-14 JP JP2021149024A patent/JP2022008381A/ja active Pending
- 2021-12-13 AU AU2021286241A patent/AU2021286241A1/en active Pending
-
2023
- 2023-09-27 JP JP2023164102A patent/JP2024001069A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
FIC20230006I1 (fi) | Vutrisiraani | |
DK3431105T3 (da) | Medicinsk sammensætning til behandling af cancer | |
DK3582853T3 (da) | Cykliske dinukleotidforbindelser til behandling af cancer | |
DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
DK3580211T3 (da) | 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer | |
DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
DK3377516T3 (da) | Sammensætning til behandling af cancer | |
DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
DK3389778T3 (da) | Indretning til fotodynamisk behandling | |
DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
DK3072835T3 (da) | Fremgangsmåde til fremføring | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
DK3458052T3 (da) | Kombinationsbehandling af cancer | |
DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
DK3302063T3 (da) | Fremgangsmåde til stimulering af frø | |
BR112018005409A2 (pt) | terapêutica de glicodirecionamento. | |
DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
DK3524255T3 (da) | Sammensætning til behandling af acne | |
DK3307267T3 (da) | Behandling af multipel sklerose |